aTyr Pharma, Inc. (NASDAQ:LIFE) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday. The brokerage presently has a $3.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price objective points to a potential upside of 15.38% from the company’s previous close.

According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “

LIFE has been the topic of several other reports. ValuEngine cut shares of aTyr Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. BMO Capital Markets set a $4.00 price target on shares of aTyr Pharma and gave the company a “hold” rating in a report on Tuesday, August 15th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. aTyr Pharma has an average rating of “Hold” and a consensus target price of $3.46.

aTyr Pharma (LIFE) traded up 0.6308% during midday trading on Tuesday, hitting $2.6164. The stock had a trading volume of 8,854 shares. The firm has a 50-day moving average of $3.24 and a 200 day moving average of $3.37. The firm’s market capitalization is $62.37 million. aTyr Pharma has a 52-week low of $2.10 and a 52-week high of $4.45.

aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.06. On average, equities analysts forecast that aTyr Pharma will post ($2.18) EPS for the current year.

WARNING: This report was originally posted by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/08/22/atyr-pharma-inc-life-upgraded-to-buy-by-zacks-investment-research.html.

A hedge fund recently raised its stake in aTyr Pharma stock. EcoR1 Capital LLC boosted its stake in aTyr Pharma, Inc. (NASDAQ:LIFE) by 134.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,292,659 shares of the biotechnology company’s stock after buying an additional 1,315,673 shares during the period. aTyr Pharma makes up approximately 2.0% of EcoR1 Capital LLC’s portfolio, making the stock its 13th largest position. EcoR1 Capital LLC owned about 9.65% of aTyr Pharma worth $8,024,000 as of its most recent SEC filing. 47.03% of the stock is owned by institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get a free copy of the Zacks research report on aTyr Pharma (LIFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.